An EU- and industry-funded project has identified potential biomarkers that could indicate how likely a drug is to cause cancer at an earlier stage of testing than is currently possible, which could save drug companies time and money - and lead to safer drugs reaching patients faster. 
Keine Kommentare:
Kommentar veröffentlichen